menu
    • menu
    [{"orgOrder":0,"company":"Ensho Therapeutics","sponsor":"EA Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"Integrin-alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ensho Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensho Therapeutics \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ensho Therapeutics \/ Ensho Therapeutics"},{"orgOrder":0,"company":"Ensho Therapeutics","sponsor":"EA Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"Integrin-alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Ensho Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensho Therapeutics \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ensho Therapeutics \/ Ensho Therapeutics"},{"orgOrder":0,"company":"Ensho Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NSHO-101","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase I","graph3":"Ensho Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensho Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ensho Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Ensho Therapeutics

    Menu

    Ensho Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ensho Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Ensho Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NSHO-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ensho to Present NSHO-101 Phase 1 Data for IBD at ECCO 2025

                            Details : EA1080 (NSHO-101) is an oral α4β7 integrin antagonist, small molecule drug candidate, which is being evaluated for the treatment of inflammatory bowel disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 14, 2025

                            Lead Product(s) : NSHO-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ensho Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Ensho Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NSHO-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Recipient : EA Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for IBD

                            Details : Ensho has the right to develop, manufacture, and commercialize a portfolio of oral alpha-4 beta-7 integrin integrin inhibitors, EA1080 (NSHO-101), globally, excluding certain Asian jurisdictions.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 27, 2024

                            Lead Product(s) : NSHO-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Recipient : EA Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ensho Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Ensho Therapeutics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NSHO-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Recipient : EA Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            EA Pharma and Ensho Sign License Agreement for EA1080, α4β7 Integrin Antagonist

                            Details : Under the terms of the license agreement, Ensho will conduct global clinical studies for EA1080, which is being evaluated in the early-stage clinical studies for inflammatory bowel disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 27, 2024

                            Lead Product(s) : NSHO-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Recipient : EA Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth